Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$26.13
$0.38(1.86%)
At close: 4:00 PM EST
$26.13
$0.38(1.86%)
Day’s Range― - ―
52-Week Range$10.62 - $38.04
Previous CloseN/A
Volume49.14K
Average Volume (3M)483.13K
Market Cap
$1.71B
Enterprise Value$1.57B
Total Cash (Recent Filing)$347.40M
Total Debt (Recent Filing)$23.09M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 17, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume780,393
30 Day Avg. Volume483,135
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue21.66
Enterprise Value/Gross Profit21.79
Enterprise Value/Ebitda-30.03
Forecast
1Y Price Target
$47.43Price Target Upside81.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$76.98M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSepterna's shift to strongly positive operating and free cash flow is a durable improvement in cash generation and discipline. This reduces near-term financing dependence, supports continued R&D funding and trial execution, and materially lowers liquidity risk versus prior years.
Conservative Balance SheetLow leverage and a sizable equity base provide financial flexibility to fund clinical programs and partnerships without heavy debt servicing. This structural strength supports multi-quarter development plans and reduces bankruptcy risk during long clinic-to-market timelines.
Advancing Clinical PipelineInitiation of SEP-479's Phase 1 is a material program milestone that advances a potentially differentiated oral GPCR therapy for hypoparathyroidism. Successful early data would validate modality and could open a durable pathway to clinical proof‑of‑concept and partnering opportunities.
Bears Say
Ongoing Operating LossesDespite top-line acceleration, persistent operating and net losses mean Septerna has yet to demonstrate sustainable profitability. Continued losses can erode capital, pressure returns, and may necessitate external funding if cash generation weakens or R&D spending ramps.
Early-Stage Clinical RiskSEP-479 remains at first‑in‑human testing; Phase 1 outcomes are primarily safety and PK and are binary for program risk. Early‑stage setbacks or unfavorable pharmacodynamics would materially delay or derail value creation and force strategy or funding adjustments.
Negative Returns On EquityNegative ROE indicates the company has not generated shareholder returns from its equity base, signalling profit-generation challenges. Over time this can limit reinvestment capacity, impair valuation drivers, and increase reliance on external capital, diluting long-term shareholder value.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $10.62 and its highest was $38.04 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.71B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on May 11, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.227.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.43.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 45,075,535 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 5.388%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.43 (81.51% Upside)
$47.43 (81.51% Upside)
Blogger Sentiment
Bullish
SEPN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 620.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 21.5%
Last 30 Days ▲ 21.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.61%
12-Months-Change
Fundamentals
Return on Equity
-9.44%
Trailing 12-Months
Asset Growth
31.26%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$47.43
▲(81.51% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
―
Ownership Overview
6.33% Insiders
8.76% Mutual Funds
77.57% Other Institutional Investors
0.41% Public Companies and
Individual Investors